Alnylam Pharmaceuticals
ALNY
#570
Rank
$43.67 B
Marketcap
$329.35
Share price
-2.03%
Change (1 day)
32.30%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Earnings for Alnylam Pharmaceuticals (ALNY)

Earnings in 2024: -$0.24 Billion USD

According to Alnylam Pharmaceuticals 's latest financial reports the company's current earnings are $3.21 Billion USD. In 2024 the company made an earning of -$0.24 Billion USD, an increase over its 2023 earnings that were of -$0.32 Billion USD. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Alnylam Pharmaceuticals from 2003 to 2024

Annual earnings

Year Earnings Change
2024-$0.24 Billion-24.59%
2023-$0.32 Billion-67.84%
2022-$0.98 Billion36.93%
2021-$0.71 Billion-8.04%
2020-$0.78 Billion-15.66%
2019-$0.92 Billion12.23%
2018-$0.82 Billion62.91%
2017-$0.51 Billion17.78%
2016-$0.43 Billion43.44%
2015-$0.3 Billion60.69%
2014-$0.19 Billion98.2%
2013-$92.95 Million
2011-$54.82 Million27.48%
2010-$43.01 Million-10.92%
2009-$48.28 Million95.77%
2008-$24.66 Million
2006-$39.51 Million-9.13%
2005-$43.48 Million34.74%
2004-$32.27 Million36.79%
2003-$23.59 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
Novartis
NVS
$16.35 B 12,447.77%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
$9.10 B 6,883.12%๐Ÿ‡ซ๐Ÿ‡ท France
Regeneron Pharmaceuticals
REGN
$5.23 B 3,913.80%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
-$0.26 Billion-293.52%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
-$47.43 Million-136.39%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
-$0.16 Billion-222.38%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
$2.15 B 1,551.35%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Arrowhead Pharmaceuticals
ARWR
$0.14 B 8.12%๐Ÿ‡บ๐Ÿ‡ธ USA